Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression.

doi:10.1002/cjp2.323

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression.

The journal of pathology. Clinical research - 1 Sept 2023

Masugi Yohei, Takamatsu Manabu, Tanaka Mariko, Hara Kensuke, Inoue Yosuke, Hamada Tsuyoshi, Suzuki Tatsunori, Arita Junichi, Hirose Yuki, Kawaguchi Yoshikuni, Nakai Yousuke, Oba Atsushi, Sasahira Naoki, Shimane Gaku, Takeda Tsuyoshi, Tateishi Keisuke, Uemura Sho, Fujishiro Mitsuhiro, Hasegawa Kiyoshi, Kitago Minoru, Takahashi Yu, Ushiku Tetsuo, Takeuchi Kengo, Sakamoto Michiie

Abstract excerpt

Alterations in KRAS, CDKN2A (p16), TP53, and SMAD4 genes have been major drivers of pancreatic carcinogenesis. The clinical course of patients with pancreatic cancer in relation to these driver alterations has not been fully characterised in large populations. We hypothesised that pancreatic carcinomas with different combinations of KRAS mutation and aberrant expression of CDKN2A, p53, and SMAD4 might show...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase Inhibitor p16

Share to Mutation

Share to Pancreatic and Hepatic Oncology Research

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Smad4 Protein

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 37291757
DOI: 10.1002/cjp2.323
PMCID: PMC10397380

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression.PMID 37291757Read ↗

Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Clinical Significance of the Genetic Landscape of Pancreatic Cancer and Implications for Identification of Potential Long-term SurvivorsSemantic proximity Read ↗

Unexpected Long-Term Survival in Resected Pancreatic Ductal Adenocarcinoma Harboring KRAS G12D/SMAD4 Co-Mutation: A Case Report and Mini-ReviewSemantic proximity Read ↗

Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.Semantic proximity Read ↗

Prognostic role and clinicopathological features of SMAD4 gene mutation in pancreatic cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Molecular characteristics of early-onset pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.Semantic proximity Read ↗

Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome.Semantic proximity Read ↗

New insight into the role of SMAD4 mutation/deficiency in the prognosis and therapeutic resistance of pancreatic ductal adenocarcinomas.Semantic proximity Read ↗

Clinicopathological Relevance of SMAD4 and RUNX3 in Patients With Resected Pancreatic Cancer.Semantic proximity Read ↗

Predicting disease recurrence in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.